Site Map

Investor Relations

• IR News
• IR Calendar
• Management Policy
  • Message from the President
  • Business Units
    • Pharmaceutical Business
  • Board Members and Executive Officers
  • Corporate Governance
    • Basic Policy on Corporate Governance
    • Basic Policy for Developing the Internal Control System
    • Corporate Governance Report
  • Business Risks
  • Stance on Information Disclosure
• IR Library
  • Financial Results
  • Presentation/Webcast
  • Integrated Report
  • Fact Book
• Financial Data
  • Financial Highlights (Consolidated)
  • Fact Sheet
• Shares & Shareholders Information
  • Share Price Chart
  • Shareholders' Meetings
  • Shareholder Returns
  • Shareholders Information
  • Analyst Coverage
  • Bonds & Ratings
• Investor Supports
  • IR Contact
  • FAQ
  • Disclaimer Regarding Forward-Looking Statements
  • IR Site Map

Research and Development

• Priority Disease Areas / Research and Development Organization
  • Priority Disease Areas
  • Research and Development Organization
• Development Pipeline / New Drugs Approved
  • Development Pipeline
  • Profiles of Major Products under Development
  • New Drugs Approved
• Drug Discovery Research / Product Development Research
  • Drug Discovery Research
  • Product Development Research
• Research Collaborations, In-licenses and Acquisitions
• Disclosure of Clinical Study Information
• Endeavors for Clinical Trials
• Glossary

Sustainability

• Top Management Commitment
• Sustainability Management
  • Material Issues
  • Business Model ― Value Creation Process
  • Together with Patients
  • Efforts toward SDGs
  • Internal Standards and Guidelines for CSR
• Promoting Healthcare Innovation
  • Development of Innovative Products and Healthcare Solutions
  • Research and Development
  • Respect for Intellectual Property
  • Provision of Stable Supplies
  • CSR-Based Procurement
  • Together with Business Partners
  • Fair Marketing
  • Corporate Regulatory Compliance and Quality Assurance
  • Medical Affairs
• Environment
  • Environmental Management
  • Basic Environmental Policies
  • Environmental Goals and Performance
  • Carbon Neutrality
  • Information Disclosure Based on TCFD Recommendations (Response to Climate Change)
  • Water・Resource Circulation
  • Pollution Prevention
  • Environmental Communications
  • Biodiversity
• Social
  • Initiatives to Improve Access to Medicines
  • Contribution to Global Health
  • Patient Support and Advocacy
  • Human Rights
  • Work Style Innovation
  • Diversity and Inclusion
  • Training and Development of Employees
  • Health, Safety and Welfare of Employees
  • Contribution to Societies and Local Communities
• Governance
  • Corporate Governance
  • Executive Remuneration
  • Evaluation of the Effectiveness of the Board of Directors
  • Information Disclosure
  • Risk Management
  • Compliance
  • Tax Transparency
• Activity Reports
• ESG Data Table
• External Evaluation
• Third-Party Assurance
• Comparison Table
  • GRI Standards Content Index
  • Comparison Table for ISO26000
  • Declaration of Conduct and ISO26000 Core Subjects

About Us

• About Us
  • Message from the President
  • About Sumitomo Pharma
  • Philosophy
  • Reboot 2027
  • Corporate Governance
    • Basic Policy on Corporate Governance
    • Basic Policy for Developing the Internal Control System
    • Corporate Governance Report
  • Risk Management / Compliance
    • Risk Management
    • Compliance
  • Business Units
    • Pharmaceutical Business
  • Corporate Profile
    • Corporate History
      • Dainippon Pharmaceutical
      • Sumitomo Pharmaceuticals
    • Board Members and Executive Officers
    • Organizational Chart
  • Key Locations / Group Companies
  • Video / Ad Library

News Room

• Press Releases
• IR News
• Notices

For the Press

• For the Press

Special Website

• Sumitomo Pharma's DX
• Our Efforts Against the Novel Coronavirus Disease (COVID-19)

Contact Us

• Inquiries about our Products (Patients and the General Public)
• Inquiries about our Products (Healthcare Professionals)
• Inquiries about Sumitomo Pharma
• Investor Inquiries
• Inquiries about Research and Development
• Inquiries about Privacy Practices and Compliance
• Other Inquiries
• Inquiry Form